Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Engineering antibodies for therapy.

J R Adair1

  • 1Celltech Research Division, Celltech Ltd, Slough Berks, U.K.

Immunological Reviews
|December 1, 1992
PubMed
Summary
This summary is machine-generated.

Antibody engineering enhances therapeutic antibody development by optimizing binding sites, effectors, and production. These advanced techniques are increasing the number of promising monoclonal antibodies entering clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recombinant antibodies for the diagnosis and therapy of human diseases.

Current opinion in drug discovery & development·2009
Same author

The therapeutic potential of plant-derived vaccines and antibodies.

Expert opinion on investigational drugs·2005
Same author

Expression of antibody fusion proteins in mammalian cells.

Methods in molecular biology (Clifton, N.J.)·1998
Same author

A humanized antibody against human cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections.

The Journal of infectious diseases·1997
Same author

Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A.

Journal of immunology (Baltimore, Md. : 1950)·1996
Same author

Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.

British journal of cancer·1995
Same journal

Diversity, Equality, and Inclusion in the naïve T Cell Receptor Repertoire.

Immunological reviews·2026
Same journal

Macrophage Plasticity and Immune Remodeling in Ischemic Heart Failure.

Immunological reviews·2026
Same journal

The T Cell Receptor: Molecular Sensor, Therapeutic Mediator and Probabilistic Driver of Adaptive Immunity.

Immunological reviews·2026
Same journal

Tissue-Resident Memory T Cells in the Heart: An Emerging Role in Chronic Inflammation.

Immunological reviews·2026
Same journal

Rethinking Immunity in Tissues: The Biology of Tertiary Lymphoid Structures.

Immunological reviews·2026
Same journal

Inflammation-Driven Lymphoid Structures: Organization, Function, and Clinical Impact Across Autoimmunity, Cancer, and Checkpoint Toxicity.

Immunological reviews·2026
See all related articles

Area of Science:

  • Biotechnology
  • Immunology
  • Pharmaceutical Science

Background:

  • Antibody-based therapeutics are crucial for treating various diseases.
  • Traditional antibody development faces challenges in specificity, affinity, and effector function.
  • Existing monoclonal antibodies in clinical trials highlight the potential of antibody therapies.

Purpose of the Study:

  • To review the impact of antibody-engineering techniques on therapeutic antibody generation.
  • To highlight key considerations for developing successful antibody-based therapeutics.
  • To discuss the growing pipeline of engineered antibodies in clinical development.

Main Methods:

  • Review of antibody-engineering techniques.
  • Analysis of critical factors in therapeutic antibody design (binding site, effector, attachment).

Related Experiment Videos

  • Assessment of production and patient response considerations.

    • Main Results:

    • Antibody-engineering techniques are actively addressing critical aspects of therapeutic antibody design.
    • These advancements are expanding the repertoire of potential monoclonal antibody therapeutics.
    • A significant number of engineered antibodies are progressing through clinical trials.

    Conclusions:

    • Antibody engineering is a vital field for advancing antibody-based therapeutics.
    • Optimizing binding sites, effectors, and production is key to therapeutic success.
    • The future will reveal the clinical impact and market presence of these engineered antibodies.